Tags Archive Navigation
icon
-
Media ReleaseNovartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19
-
Media ReleaseNovartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
-
Media ReleaseNovartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms
-
Media ReleaseNovartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
-
Media ReleaseAveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
-
Media ReleaseNovartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
-
Media ReleaseNovartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease
-
Media ReleaseNovartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
-
Media ReleaseNovartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery
-
Media ReleaseNovartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis
-
Media ReleaseNovartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
-
Media ReleaseNovartis Resolves Legacy FCPA Investigations
Pagination
- ‹ Previous page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- …
- 31
- › Next page